Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that preliminary results of the Phase I NATHALI-01 clinical trial evaluating UCART20x22 in patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL) and updated results of the Phase I BALLI-01 clinical trial evaluating UCART22 in patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia, (r/r B-ALL) will be presented at the American Society of Hematology 65th Annual Meeting (ASH 2023), that will take place on December 9-12, 2023 in San Diego (CA) and online.
These data will be presented in two poster sessions:
Poster Presentation (P2110)
Title: Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)
Session Name: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I
Presenter: Dr. Jeremy Abramson (Massachusetts General Hospital Cancer Center)
Date/Time: Saturday, December 9, 2023 at 5:30 - 7:30 PM PT at San Diego Convention Center, Halls G-H
The poster presentation highlights the following data:
Poster Presentation (P4847)
Title: Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Session Name: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III
Presenter: Dr. Nitin Jain (University of Texas MD Anderson Cancer Center)
Date/Time: Monday, December 11, 2023 at 6:00 - 8:00 PM PT at San Diego Convention Center, Halls G-H
The poster presentation highlights the following data:
Posted In: CLLS